Scisparc

Scisparc Forward P/E

The Forward P/E Ratio of Scisparc (SPRC) as of Nov 21, 2026 is -0.22. In the previous year, Forward P/E Ratio was -0.42 — a change of -48.40% (higher).

Forward P/E

-0.22

YoY

-48.40%

Last updated:

Forward P/E Ratio of Scisparc is 2025 -0.22 . Forward P/E Ratio of Scisparc was 2024 -0.42 . It decreases by -48.40% higher compared to the previous year.

The Scisparc Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-0.31 USD
Jan 1, 2019
-0.49 USD
Jan 1, 2020
-0.75 USD
Jan 1, 2021
-0.45 USD
Jan 1, 2022
-1.02 USD
Jan 1, 2023
-0.51 USD
Jan 1, 2024
-0.42 USD
Jan 1, 2025
-0.22 USD
The Scisparc Forward P/E history
YEARForward P/EYoY
-0.22-48.40%
-0.42-18.49%
-0.51-49.39%
-1.02+123.80%
-0.45-39.54%
-0.75+52.89%
-0.49+58.95%
-0.31-26.74%
-0.42-68.12%
-1.32+27.12%
-1.04-26.85%
-1.42—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? SciSparc Ltd develops cannabinoid-based pharmaceuticals including THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain. The company monetizes through drug development programs targeting specific medical conditions, with pharmaceutical companies and research institutions as primary buyers of these development assets. The firm's revenue streams derive from licensing agreements and partnerships with biopharmaceutical entities seeking to advance cannabinoid-based therapies for unmet medical needs. SciSparc focuses on repurposing Dronabinol into multiple therapeutic applications, creating a diversified portfolio of drug candidates. Its products target neurological disorders, sleep disorders, and infectious diseases, appealing to healthcare providers and patients requiring innovative treatments. The company's business model relies on generating revenue through the sale of development-stage drug assets to larger pharmaceutical firms rather than direct patient sales. The firm's pipeline includes four distinct drug candidates, each addressing different medical conditions. THX-110 targets Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 addresses Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 targets infectious diseases; and THX-160 focuses on pain management. These assets are marketed to biopharmaceutical companies as potential additions to their therapeutic portfolios. Scisparc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scisparc stock

Forward P/E Ratio of Scisparc is -0.22 in 2025.

Forward P/E Ratio of Scisparc changed from -0.42 to -0.22, representing a -48.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Scisparc since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Scisparc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Scisparc

All Key Metrics — Scisparc